Allopurinol/paracetamol/sodium-valproate

  • PDF / 169,694 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 37 Downloads / 151 Views

DOWNLOAD

REPORT


1 S

Stevens-Johnson syndrome and toxic epidermal necrolysis: 3 case reports A retrospective study of 213 patients (hospitalised at Huashan hospital affiliated with Fudan university, China between January 2008 and December 2018) described 3 male patients aged 50–88 years, who developed Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) during treatment with allopurinol, paracetamol or sodium valproate [indications, routes, dosages and times to reactions onsets not stated]. The 88-year-old man, who had chronic renal dysfunction, hypertension, chronic heart dysfunction, diabetes mellitus and gout, received allopurinol. However, he developed SJS/TEN. Thus, he was admitted and was treated with methylprednisolone. The severity of illness scoring system for TEN (SCORTEN) was 5. His hospital stay was of 10 days. He died due to multiple organ dysfunction syndrome. The 76-year-old man, who had hypertension and chronic obstructive pulmonary disease, received paracetamol. However, he developed SJS/TEN. Thus, he was admitted and was treated with methylprednisolone. The severity of illness scoring system for TEN (SCORTEN) was 4. His hospital stay was of 5 days. He died due to acute renal dysfunction. The 50-year-old man, who had pneumonia, electrolyte disturbance, acute liver failure and chronic anaemia, received sodium valproate. However, he developed TEN. Thus, he was admitted and was treated with methylprednisolone. The severity of illness scoring system for TEN (SCORTEN) was 4. His hospital stay was of 5 days. He died due to multiple organ dysfunction syndrome. Yang L, et al. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. Burns 46: 959-969, No. 4, Jun 2020. Available from: 803497691 URL: http://doi.org/10.1016/j.burns.2019.10.008

0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 22 Aug 2020 No. 1818

Data Loading...